Cancer: Effect of vascular endothelial growth factor in the treatment of metastatic thyroid cancer

!---- some multi-target tyrosine kinase inhibitors (TKIs) showed antitumor activity in patients with thyroid cancer resistant to radioactive iodine (RAI), in part because these TKIs inhibited the angiogenesis of these vascular tumorsvascular endothelial growth factor (VEGF) trap (VT) is a recombinantly produced fusion protein consisting entirely of veGF receptors 1 and 2 extracellular human sequences and human immunoglobulin 1taking into account the observed activity of TKIs targeting VEGF, it is necessary to evaluate VT in thyroid cancer patientsthis study is a single-body, phase 2, Simon 2-stage design (21 to 41 patients), based on objective response rate and/or six-month progression-free survival as the primary endpointeligible patients need progression, RAI refractory and/or s/18 F fluorooxethlygine intolerance, recurrence and/or metastatic, non-myelin, non-tumor thyroid cancer;a dose of VT of 4 mg/kg intravenously every 14 daysresults, a total of 40 patients were included in the analysis24 of them were thyroid papilloma cancer, 2 were thyroid follicle cancer and 11 were Hurthle cell thyroid cancerthe last three tumors were classified as poorly differentiateddid not notice a full and/or partial response; 34 patients received stable disease and 6 patients had the best response to progressionof the 34 patients with stable disease, 16 were still in the study for more than 6 months and 6 were still in the study for more than 12 monthsThe median time oftreatment is 4.1 months (range, 0.6-30.8 months)the above, the results show that, unlike TKIs, TKIs have shown a reaction in this case, and to the author's knowledge, no response to the use of single drug VT has been observed to dateit does not seem to be a promising drug for thyroid cancer patients